Literature DB >> 6095322

Dishabituating effects of an ACTH 4-9 analog in a vigilance task.

J Born, G Fehm-Wolfsdorf, M Schiebe, B Rockstroh, H L Fehm, K H Voigt.   

Abstract

Ten male adults were tested in a vigilance task after oral administration of either 40 mg ACTH 4-9 analog, ORG 2766, or placebo in a single three hour session. EEG spectra, averaged auditory evoked responses, heart rate and blood pressure, and behavioral performance were measured during a vigilance task. ACTH 4-9 analog treatment led to a decreased inhibition of the central nervous system across the experiment: to less mean power density and faster center frequencies within the alpha band, and to less attenuated amplitudes of the components of the auditory vertex potential (P50, N100, P200). Treatment effects increased towards the end of the session and might indicate a dishabituating effect, probably due to suppression of inhibitory influences of limbic structures on mesencephalic reticular activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095322     DOI: 10.1016/s0091-3057(84)80032-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  3 in total

1.  Dose-dependent influences on electrophysiological signs of attention in humans after neuropeptide ACTH 4-10.

Authors:  J Born; W Bräuninger; G Fehm-Wolfsdorf; K H Voigt; P Pauschinger; H L Fehm
Journal:  Exp Brain Res       Date:  1987       Impact factor: 1.972

2.  Influences of peripheral adrenocorticotropin 1-39 (ACTH) and human corticotropin releasing hormone (h-CRH) on human auditory evoked potentials (AEP).

Authors:  J Born; B Bathelt; R Pietrowsky; P Pauschinger; H L Fehm
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Diurnal pituitary-adrenal activity during schedule-induced polydipsia of water and ethanol in cynomolgus monkeys (Macaca fascicularis).

Authors:  Christa M Helms; Steven W Gonzales; Heather L Green; Kendall T Szeliga; Laura S M Rogers; Kathleen A Grant
Journal:  Psychopharmacology (Berl)       Date:  2013-03-19       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.